Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Rathcke, Camilla Noelle ^a   Holmkvist, Johan ^b   Jøorgensen, Torben ^a   Borch Johnsen, Knut ^c   Hansen, Torben ^b   Pedersen, Oluf Borbye ^b,d,e   Vestergaard, Henrik ^a,e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HAGEDORN RESEARCH INSTITUTE   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHITINASE 3 LIKE 1 PROTEIN; GLYCOPROTEIN; UNCLASSIFIED DRUG; CHI3L1 PROTEIN, HUMAN; MICROSATELLITE DNA;

ADULT; ARTICLE; COHORT ANALYSIS; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; HAPLOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; RISK FACTOR;

STENO;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUCOSE TOLERANCE TEST; GLYCOPROTEINS; HAPLOTYPES; HUMANS; INSULIN RESISTANCE; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; RISK FACTORS;

EID: 65549120282     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005469     Document Type: Article

References (33)

1. McCarthy MI (2003) Growing evidence for diabetes susceptibility genes from genome scan data. Curr Diab Rep 3: 159-67.
2. McCarthy MI, Zeggini E (2006) Genetics of type 2 diabetes. Curr Diab Rep 6: 147-54.
3. McCarthy MI, Zeggini E (2007) Genome-wide association scans for Type 2 diabetes: new insights into biology and therapy. Trends Pharmacol Sci 28: 598-601.
4. Langefeld CD, Wagenknecht LE, Rotter JI, Williams AH, Hokanson JE, et al. (2004) Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study. Diabetes 53: 1170-4.
5. Rathcke CN, Vestergaard H (2006) YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55: 221-7.
6. Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55: 53-9.
7. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, et al. (2009) Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol. In Press.
8. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H (2009) YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with Type 1 Diabetes and increases with levels of albuminuria. Diabetes Care. In Press.
9. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM (2007) A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 101: 1563-71.
10. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, et al. (2007) A genome-wide association study of global gene expression. Nat Genet 39: 1202-7.
11. Ober C, Tan Z, Sun Y, Possicj JD, Pan L, et al. (2008) Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 358: 1682-91.
12. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, et al. (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10: 377-86.
13. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-53.
14. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, et al. (2005) Efficiency and power in genetic association studies. Nat Genet 37: 1217-23.
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-75.
16. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316: 1331-6.
17. Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53: 172-209.
18. Shackelton LM, Mann DM, Millis AJ (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270: 13076-83.
19. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250: 168-73.
20. Millis AJ, Hoyle M, Kent L (1986) In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 127: 366-72.
21. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S (2007) Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18: 391-6.
22. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, et al. (2008) Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19: 257-63.
23. Meigs JB, Hu FB, Rifai N, Manson JE (2004) Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291: 1978-86.
24. Pickup JC (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27: 813-23.
25. Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48: 1038-50.
26. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-28.
27. Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM (2003) Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108: 1822-30.
28. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110: 380-5.
29. Ingelsson E, Hulthe J, Lind L (2008) Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest 38: 502-9.
30. Dupuis J, Larson MG, Vasan RS, Massaro JM, Wilson PW, et al. (2005) Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q. Atherosclerosis 182: 307-14.
31. Pantsulaia I, Trofimov S, Kobyliansky E, Livshits G (2002) Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population. Cytokine 19: 138-46.
32. de Maat MP, Bladbjerg EM, Hjelmborg JB, Bathum L, Jespersen J, et al. (2004) Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 24: 2168-73.
33. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, et al. (2002) Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 53: 1029-34.